감염증 진단 시장 예측(-2030년) : 제품별, 질환별, 기술별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Infectious Disease Diagnostics Market is accounted for $23.63 billion in 2024 and is expected to reach $42.78 billion by 2030 growing at a CAGR of 10.4% during the forecast period. Infectious disease diagnostics refers to the process of identifying the presence of pathogens, such as bacteria, viruses, fungi, or parasites, in a person's body to diagnose infectious diseases. These diagnostics involve various techniques and methods aimed at detecting specific pathogens or their markers, often through analyzing bodily fluids, tissues, or other samples. Rapid diagnostic tests (RDTs) are also utilized for quick identification in settings with limited resources. Accurate and timely diagnosis of infectious diseases is crucial for effective patient management, initiation of appropriate treatment, implementation of infection control measures, and disease surveillance.

According to the Centers for Disease Control and Prevention (CDC), in 2018, it was reported that approximately 1.7 million infections and 99,000 associated deaths occur every year in American hospitals. According to the U.S. Food and Drug Administration (FDA), in 2020, it was reported that around 300,000 individuals aged 50 and above are diagnosed with pneumococcal pneumonia, every year.

Market Dynamics:

Driver:

Growing demand for point-of-care testing

Point-of-care testing offers rapid, convenient, and decentralized testing solutions, allowing for quick diagnosis and timely treatment decisions at the patient's bedside or in community settings. This shift towards POCT is driven by several factors, including the need for faster turnaround times, especially in infectious disease outbreaks or pandemics like COVID-19. Additionally, POCT reduces the burden on centralized laboratory facilities and healthcare infrastructure, making testing more accessible to underserved populations and remote areas.

Restraint:

High cost of diagnostic tests

The high cost of diagnostic tests poses a significant barrier to the growth of the Infectious Disease Diagnostics Market. These costs encompass various aspects such as test development, manufacturing, and distribution, all of which contribute to the final price borne by patients and healthcare systems. For many individuals, especially in low- and middle-income countries, these expenses are prohibitive, leading to delayed or missed diagnoses and subsequent treatment. However, high costs can strain healthcare budgets, limiting access to essential diagnostic services.

Opportunity:

Rise in public health awareness

The rise in public health awareness has substantially contributed to the growth of the Infectious Disease Diagnostics Market. With an increasing understanding of the importance of early detection and prevention of infectious diseases, individuals and governments alike are investing more resources into diagnostic technologies. The global health crises, such as the COVID-19 pandemic, have highlighted the critical role of diagnostic testing in containing outbreaks and guiding public health responses. Consequently, there is a growing emphasis on the development and adoption of rapid, accurate, and cost-effective diagnostic solutions, driving innovation in the infectious disease diagnostics market and fostering collaborations between healthcare providers, research institutions and diagnostic companies.

Threat:

Complexity of diagnostic procedures

The complexity of diagnostic procedures poses a significant obstacle in the growth of the Infectious Disease Diagnostics Market. These complexities encompass various facets, including the technical intricacies involved in testing methodologies, lengthy turnaround times for obtaining results, and the requirement for skilled personnel to perform and interpret tests accurately. However, the diversity of infectious agents and their evolving nature further complicates diagnostic protocols, necessitating continuous updates and adaptations to detection techniques. These complexities not only increase the cost burden on healthcare systems but also impede timely and effective diagnosis and treatment of infectious diseases.

Covid-19 Impact:

The Covid-19 pandemic significantly impacted the infectious disease diagnostics market. There was an unprecedented surge in demand for diagnostic tests to detect the virus, leading to a rapid expansion of the market. The pandemic highlighted the importance of diagnostic testing in controlling infectious diseases, leading to increased investment in research and development for novel diagnostic technologies. However, the pandemic also disrupted supply chains and distribution networks, causing temporary shortages of testing kits and reagents.

The Fungal Infections segment is expected to be the largest during the forecast period

The fungal infections segment is anticipated to be the largest in the infectious disease diagnostics market during the forecast period due to the rising prevalence of invasive fungal diseases, particularly among immunocompromised individuals. Increased awareness, advancements in diagnostic technologies, and the need for timely and accurate identification of fungal pathogens drive market growth. The growing incidence of hospital-acquired infections and the high morbidity and mortality rates associated with fungal infections further contribute to the segment's expansion.

The Next-generation Sequencing segment is expected to have the highest CAGR during the forecast period

Next-generation Sequencing segment is expected to have the highest CAGR during the forecast period by enabling rapid and comprehensive analysis of pathogens' genetic material. This technology allows for the simultaneous detection and characterization of multiple infectious agents, including bacteria, viruses, fungi, and parasites, in a single test. By sequencing the entire genome or specific regions of pathogens, NGS can provide valuable insights into their genetic diversity, drug resistance profiles, and epidemiological patterns. This comprehensive approach enhances the accuracy and efficiency of infectious disease diagnosis, particularly in cases where traditional methods may fail to identify the causative agent or distinguish between closely related strains. Additionally, NGS facilitates the detection of emerging infectious diseases and the monitoring of outbreaks in real-time, empowering healthcare professionals to implement timely and targeted interventions for better disease management and control.

Region with largest share:

Asia Pacific region commanded the largest share of the market throughout the extrapolated period. As populations age, there's a natural increase in susceptibility to infectious diseases due to weakened immune systems and other age-related factors. This demographic shift creates a higher demand for diagnostic tools and services to effectively detect and manage infectious diseases among the elderly. Additionally, factors such as urbanization, changing lifestyles, and increased access to healthcare facilities further contribute to the expansion of the infectious disease diagnostics market in the region.

Region with highest CAGR:

Europe region is poised to hold profitable growth during the projection period. Through stringent regulatory frameworks, such as the European Union's In Vitro Diagnostic Regulation (IVDR), authorities ensure the quality, safety, and efficacy of diagnostic tests. These regulations not only set high standards for product development and manufacturing but also facilitate timely approvals and market access for innovative diagnostic technologies. Moreover, compliance with these regulations fosters trust among healthcare professionals and patients, thereby driving the regional adoption of advanced diagnostic solutions.

Key players in the market

Some of the key players in Infectious Disease Diagnostics market include Bio-Rad Laboratories, Inc, Hologic, Inc, Luminex Corporation, Abbott Laboratories, GenMark Diagnostics, Inc, PerkinElmer, Inc, Thermo Fisher Scientific Inc, Bruker Corporation, Sysmex Corporation, Nanosphere Health Sciences Inc, Trinity Biotech plc, InBios International, Inc and Meridian Bioscience, Inc.

Key Developments:

In February 2023, Abbott to acquire Cardiovascular Systems for $837.6 mln. The deal will help Abbott gain access to CSI's minimally invasive device to treat blocked arteries.

In May 2022, Quidel Corporation a US-based company that provides rapid diagnostic testing solutions, cellular-based virology assays, and molecular diagnostic systems, has acquired Ortho Clinical Diagnostics and the succeeding business groups.

Products Covered:

• Assays & Reagents
• Kits
• Consumables
• Instruments
• Software & Services

Diseases Covered:

• Bacterial Infections
• Viral Infections
• Fungal Infections
• Parasitic Infections
• Other Diseases

Technologies Covered:

• Immunodiagnostics
• Microbiology
• Polymerase Chain Reaction
• Next-generation Sequencing
• Other Technologies

End Users Covered:

• Diagnostic Laboratories
• Academic Research Institutes
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Infectious Disease Diagnostics Market, By Product

• 5.1 Introduction
• 5.2 Assays & Reagents
• 5.3 Kits
• 5.4 Consumables
• 5.5 Instruments
• 5.6 Software & Services

6 Global Infectious Disease Diagnostics Market, By Disease

• 6.1 Introduction
• 6.2 Bacterial Infections
• 6.3 Viral Infections
• 6.4 Fungal Infections
• 6.5 Parasitic Infections
• 6.6 Other Infectious Diseases

7 Global Infectious Disease Diagnostics Market, By Technology

• 7.1 Introduction
• 7.2 Immunodiagnostics
• 7.3 Microbiology
• 7.4 Polymerase Chain Reaction
• 7.5 Next-generation Sequencing
• 7.6 Other Technologies

8 Global Infectious Disease Diagnostics Market, By End User

• 8.1 Introduction
• 8.2 Diagnostic Laboratories
• 8.3 Academic Research Institutes
• 8.4 Hospitals
• 8.5 Other End Users

9 Global Infectious Disease Diagnostics Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Bio-Rad Laboratories, Inc
• 11.2 Hologic, Inc
• 11.3 Luminex Corporation
• 11.4 Abbott Laboratories
• 11.5 GenMark Diagnostics, Inc
• 11.6 PerkinElmer, Inc
• 11.7 Thermo Fisher Scientific Inc
• 11.8 Bruker Corporation
• 11.9 Sysmex Corporation
• 11.10 Nanosphere Health Sciences Inc
• 11.11 Trinity Biotech plc
• 11.12 InBios International, Inc
• 11.13 Meridian Bioscience, Inc